Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.566 USD | +3.73% | -4.14% | -6.20% |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
Mar. 29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 17.83M |
---|---|---|---|---|---|
Net income 2024 * | -40M | Net income 2025 * | -42M | EV / Sales 2024 * | - |
Net Debt 2024 * | 2.46M | Net cash position 2025 * | 39.69M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.62
x | P/E ratio 2025 * |
-0.55
x | Employees | 43 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.05% |
1 day | +3.73% | ||
1 week | -4.14% | ||
Current month | -17.61% | ||
1 month | -16.99% | ||
3 months | -8.68% | ||
6 months | -13.60% | ||
Current year | -6.20% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Iwicki
CEO | Chief Executive Officer | 57 | 15-02-28 |
Mary Reumuth
DFI | Director of Finance/CFO | 48 | 14-01-31 |
Todd Bazemore
PSD | President | 53 | 17-11-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Koven
BRD | Director/Board Member | 66 | 17-09-27 |
Gregory Perry
BRD | Director/Board Member | 63 | 18-03-04 |
Howard Rosen
BRD | Director/Board Member | 66 | 14-01-05 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 6.33 | -3.95% | 12,630 |
24-04-19 | 6.59 | -3.23% | 8,535 |
24-04-18 | 6.81 | -0.41% | 9,250 |
24-04-17 | 6.838 | -0.17% | 14,764 |
24-04-16 | 6.85 | -2.14% | 17,867 |
Delayed Quote Nasdaq, April 23, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.20% | 17.83M | |
+27.92% | 659B | |
+27.68% | 557B | |
-4.59% | 359B | |
+16.38% | 322B | |
+9.39% | 297B | |
+6.30% | 215B | |
+4.80% | 210B | |
-6.05% | 200B | |
-8.58% | 149B |
- Stock Market
- Equities
- KALA Stock